Acceder

Bibliografías temáticas / Epstein-Barr virus. Epstein-Barr virus / Artículos de revistas

Siga este enlace para ver otros tipos de publicaciones sobre el tema: Epstein-Barr virus. Epstein-Barr virus.

Artículos de revistas sobre el tema "Epstein-Barr virus. Epstein-Barr virus"

Autor: Grafiati

Publicado: 4 de junio de 2021

Última modificación: 1 de febrero de 2022

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Epstein-Barr virus. Epstein-Barr virus".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.

1

Rickinson, Alan. "Epstein–Barr virus". Virus Research 82, n.º 1-2 (diciembre de 2001): 109–13. http://dx.doi.org/10.1016/s0168-1702(01)00436-1.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

2

Crawford, Dorothy H. "Epstein–Barr Virus". Lancet Infectious Diseases 6, n.º 3 (marzo de 2006): 138. http://dx.doi.org/10.1016/s1473-3099(06)70408-x.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

3

Nicolas, Jean-Claude. "Virus Epstein-Barr". EMC - Biologie Médicale 1, n.º 1 (enero de 2006): 1–8. http://dx.doi.org/10.1016/s2211-9698(06)76372-5.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

4

Rugge, Massimo y Robert M. Genta. "Epstein-Barr Virus". Journal of Clinical Gastroenterology 29, n.º 1 (julio de 1999): 3–5. http://dx.doi.org/10.1097/00004836-199907000-00002.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

5

Schooley, R. T. "Epstein—Barr virus". Current Opinion in Infectious Diseases 2, n.º 2 (abril de 1989): 267–71. http://dx.doi.org/10.1097/00001432-198904000-00018.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

6

Sangüeza, Omar P. "Epstein-Barr Virus". Archives of Dermatology 133, n.º 9 (1 de septiembre de 1997): 1156. http://dx.doi.org/10.1001/archderm.1997.03890450106013.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

7

Junker, A. K. "Epstein-Barr Virus". Pediatrics in Review 26, n.º 3 (1 de marzo de 2005): 79–85. http://dx.doi.org/10.1542/pir.26-3-79.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

8

Jenson, H. B. "Epstein-Barr Virus". Pediatrics in Review 32, n.º 9 (1 de septiembre de 2011): 375–84. http://dx.doi.org/10.1542/pir.32-9-375.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

9

Gequelin, Luciana Cristina Fagundes, Irina N. Riediger, Sueli M. Nakatani, Alexander W. Biondo y Carmem M. Bonfim. "Epstein-Barr virus". Revista Brasileira de Hematologia e Hemoterapia 33, n.º 5 (2011): 383–88. http://dx.doi.org/10.5581/1516-8484.20110103.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

10

Alfieri, Caroline. "Epstein‐Barr Virus:Epstein‐Barr Virus". Clinical Infectious Diseases 43, n.º 5 (septiembre de 2006): 669–70. http://dx.doi.org/10.1086/506445.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

11

Mardanpour, Keykhosro, Mahtab Rahbar, Sourena Mardanpour, Sidegheh Khazaei y Mansour Rezaei. "Co-expression of Epstein–Barr virus–encoded RNA1 and viral latent membrane protein 1 in osteosarcoma: A novel insight of predictive markers". Tumor Biology 42, n.º 11 (noviembre de 2020): 101042832097424. http://dx.doi.org/10.1177/1010428320974247.

Texto completo

Resumen

Epstein–Barr virus is an etiologic agent of several malignancies. In this study, we explored the association of Epstein–Barr virus–encoded RNA1 and Epstein–Barr virus latent membrane protein 1 co-expression with osteosarcoma. Epstein–Barr virus–encoded RNA1 expression in tumor cells was quantified using reverse transcriptase polymerase chain reaction and in situ hybridization and Epstein–Barr virus latent membrane protein 1 expression was measured using immunohistochemistry staining. There was a statistically significant association between Epstein–Barr virus latent membrane protein 1 and Epstein–Barr virus–encoded RNA1 co-expression and characteristics of osteosarcoma such as nodal stage (p < 0.04), metastasis (p < 0.04), Ki67 index (p < 0.03), and tumor stage (p < 0.05). Co-expression of Epstein–Barr virus–encoded RNA1 and Epstein–Barr virus latent membrane protein 1 in tumors correlated with advanced osteosarcoma and indicated the aggressiveness of bone sarcoma.

Los estilos APA, Harvard, Vancouver, ISO, etc.

12

Lee, Yong-Sik. "Nasopharyngeal carcinoma and Epstein-Barr virus". Journal of Clinical Otolaryngology Head and Neck Surgery 7, n.º 1 (mayo de 1996): 101–11. http://dx.doi.org/10.35420/jcohns.1996.7.1.101.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

13

Garrido-Colmenero, Cristina, Salvador Arias-Santiago, Gonzalo Blasco-Morente y Israel Pérez-López. "Acute urticaria caused by Epstein Barr virus". ACTUALIDAD MEDICA 99, n.º 793 (31 de diciembre de 2014): 175. http://dx.doi.org/10.15568/am.2014.793.cd04.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

14

Durbin, W. A. y J. L. Sullivan. "Epstein-Barr Virus Infection". Pediatrics in Review 15, n.º 2 (1 de febrero de 1994): 63–68. http://dx.doi.org/10.1542/pir.15-2-63.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

15

Knecht, Hans, Christoph Berger, A. Samer Al-Homsi, Catherine McQuain y Pierre Brousset. "Epstein-Barr virus oncogenesis". Critical Reviews in Oncology/Hematology 26, n.º 2 (julio de 1997): 117–35. http://dx.doi.org/10.1016/s1040-8428(97)00016-4.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

16

Paris-Hamelin, A. "Le virus Epstein-Barr". Immuno-analyse & Biologie Spécialisée 7, n.º 4 (septiembre de 1992): 9–16. http://dx.doi.org/10.1016/s0923-2532(05)80146-2.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

17

Rhem, Marcus N., Kirk R. Wilhelmus y Dan B. Jones. "Epstein-Barr virus dacryoadenitis". American Journal of Ophthalmology 129, n.º 3 (marzo de 2000): 372–75. http://dx.doi.org/10.1016/s0002-9394(99)00351-7.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

18

Ternák, G. "Epstein-Barr virus reactivation". Lancet Infectious Diseases 3, n.º 5 (mayo de 2003): 271. http://dx.doi.org/10.1016/s1473-3099(03)00603-0.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

19

Cohen, Jeffrey I. "Epstein–Barr Virus Infection". New England Journal of Medicine 343, n.º 7 (17 de agosto de 2000): 481–92. http://dx.doi.org/10.1056/nejm200008173430707.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

20

Wilmes, E. y H. Wolf. "Epstein-Barr Virus Infektionen". Laryngo-Rhino-Otologie 68, n.º 01 (enero de 1989): 36–43. http://dx.doi.org/10.1055/s-2007-998282.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

21

Chen, Zong-ming E., Rajesh Shah, Gary R. Zuckerman y Hanlin L. Wang. "Epstein-Barr Virus Gastritis". American Journal of Surgical Pathology 31, n.º 9 (septiembre de 2007): 1446–51. http://dx.doi.org/10.1097/pas.0b013e318050072f.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

22

Cohen, Jeffrey I. "Epstein–barr virus vaccines". Clinical & Translational Immunology 4, n.º 1 (23 de enero de 2015): e32. http://dx.doi.org/10.1038/cti.2014.27.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

23

Cohen, Jeffrey I. "Epstein–Barr virus vaccines". Clinical & Translational Immunology 4, n.º 4 (17 de abril de 2015): e36. http://dx.doi.org/10.1038/cti.2015.4.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

24

Oki, Masayuki, Hideki Ozawa y Atsushi Takagi. "Epstein-Barr Virus Gastritis". Internal Medicine 56, n.º 6 (2017): 743–44. http://dx.doi.org/10.2169/internalmedicine.56.7846.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

25

Kofteridis, Diamantis P., Mairi Koulentaki, Antonios Valachis, Maria Christofaki, Elias Mazokopakis, George Papazoglou y George Samonis. "Epstein Barr Virus hepatitis". European Journal of Internal Medicine 22, n.º 1 (febrero de 2011): 73–76. http://dx.doi.org/10.1016/j.ejim.2010.07.016.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

26

Jahann, Darius y Paul Martin. "Epstein-Barr Virus Pancreatitis". American Journal of Gastroenterology 107 (octubre de 2012): S333—S334. http://dx.doi.org/10.14309/00000434-201210001-00810.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

27

&NA;. "Epstein–Barr virus (EBV)". Advances in Anatomic Pathology 1, n.º 2 (septiembre de 1994): 108. http://dx.doi.org/10.1097/00125480-199409000-00019.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

28

Hutt-Fletcher, Lindsey M. "Epstein-Barr Virus Entry". Journal of Virology 81, n.º 15 (25 de abril de 2007): 7825–32. http://dx.doi.org/10.1128/jvi.00445-07.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

29

POTTGIESSER, TORBEN, BERND WOLFARTH, YORCK OLAF SCHUMACHER y GEORG BAUER. "Epstein-Barr Virus Serostatus". Medicine & Science in Sports & Exercise 38, n.º 10 (octubre de 2006): 1782–91. http://dx.doi.org/10.1249/01.mss.0000230122.91264.3f.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

30

Bowdre, Jean H. "Epstein-Barr virus serology". Clinical Immunology Newsletter 11, n.º 6 (junio de 1991): 81–85. http://dx.doi.org/10.1016/0197-1859(91)90037-s.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

31

MORGAN, A. "Epstein — Barr virus vaccines". Vaccine 10, n.º 9 (1992): 563–71. http://dx.doi.org/10.1016/0264-410x(92)90434-l.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

32

Sanyal, D., G. Kudesia y M. Young. "Epstein-Barr virus encephalitis". Journal of Infection 22, n.º 1 (enero de 1991): 101–2. http://dx.doi.org/10.1016/0163-4453(91)91290-e.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

33

Bauer, Claudia C., Stephan W. Aberle, Theresia Popow-Kraupp, Magdalena Kapitan, Hanns Hofmann y Elisabeth Puchhammer-Stöckl. "Serum epstein-barr virus DNA load in primary epstein-barr virus infection". Journal of Medical Virology 75, n.º 1 (12 de noviembre de 2004): 54–58. http://dx.doi.org/10.1002/jmv.20237.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

34

Holovan, A. V., K. S. Naumenko, F. V. Muchnyk, G. V. Baranova, L. B. Zelena y S. D. Zagorodnya. "Antiviral Activity of Extracts from Wild Grasses against Epstein-Barr Virus and Induction of Apoptosis in Epstein-Barr Virus-Positive Lymphoblastoid Cells". Mikrobiolohichnyi Zhurnal 82, n.º 4 (17 de agosto de 2020): 71–79. http://dx.doi.org/10.15407/microbiolj82.04.071.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

35

Rota, S., I. Fidan, T. Muderris, E. Yesilyurt y Z. Lale. "Cytokine levels in patients with Epstein–Barr virus associated laryngeal carcinoma". Journal of Laryngology & Otology 124, n.º 9 (8 de junio de 2010): 990–94. http://dx.doi.org/10.1017/s0022215110001416.

Texto completo

Resumen

AbstractObjective:Some researchers have suggested that Epstein–Barr virus may play a role in the pathogenesis of laryngeal malignancies. In order to clarify the role of cytokines in this disease context, the current study aimed to determine the serum levels of cytokines in Epstein–Barr virus DNA positive patients with laryngeal carcinoma.Subjects:The study included 10 patients with diagnosed laryngeal carcinoma and Epstein–Barr virus DNA positive tumour tissue samples. The control group comprised 10 Epstein–Barr virus DNA negative patients diagnosed with laryngeal carcinoma, 10 patients with acute Epstein–Barr virus infection and 10 healthy individuals.Method:Serum cytokine levels were determined by enzyme-linked immunosorbent assay.Results:The Epstein–Barr virus DNA positive and negative laryngeal carcinoma patients showed no differences regarding serum levels of the following cytokines: interleukins 1β, 2, 6 and 12, tumour necrosis factor α, and interferon γ. However, serum levels of interleukin 10 and transforming growth factor β1 were significantly higher in Epstein–Barr virus DNA positive laryngeal carcinoma patients compared with Epstein–Barr virus DNA negative laryngeal carcinoma patients (p < 0.05).Conclusion:Our results suggest that the cytokines interleukin 10 and transforming growth factor β1 may act as growth factors in Epstein–Barr virus related laryngeal carcinoma. These cytokines may thus represent potential targets for molecular therapeutic treatment for laryngeal carcinoma; they may also be useful as indicators of disease prognosis.

Los estilos APA, Harvard, Vancouver, ISO, etc.

36

Afanasenkova, T. E., E. E. Dubskaya y S. M. Bazhenov. "The prognosis of chronic erosive gastritis associated with Helicobacter pylori and Epstein-Barr". Experimental and Clinical Gastroenterology, n.º 12 (20 de diciembre de 2019): 61–64. http://dx.doi.org/10.31146/1682-8658-ecg-172-12-61-64.

Texto completo

Resumen

Аim. To study the severity of chronic erosive gastritis associated with Helicobacter pylori and Epstein-Barr virus depending on the number of copies of Epstein-Barr virus in biopsies of gastric mucosa. Materials and methods. The severity of chronic erosive gastritis associated with Helicobacter pylori in the presence and absence of Epstein-Barr virus in the gastric mucosa was compared in 65 patients, divided into 4 groups depending on the detection of Epstein-Barr virus in the gastric mucosa. Result. the presence of Epstein-Barr virus in the gastric mucosa aggravates the course of chronic erosive gastritis associated with Helicobacter pylori.

Los estilos APA, Harvard, Vancouver, ISO, etc.

37

Kawaguchi, H., T. Miyashita, H. Herbst, G. Niedobitek, M. Asada, M. Tsuchida, R. Hanada, A. Kinoshita, M. Sakurai y N. Kobayashi. "Epstein-Barr virus-infected T lymphocytes in Epstein-Barr virus-associated hemophagocytic syndrome." Journal of Clinical Investigation 92, n.º 3 (1 de septiembre de 1993): 1444–50. http://dx.doi.org/10.1172/jci116721.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

38

Kaizaki, Yasuharu, Shinji Sakurai, Ja-Mun Chong y Masashi Fukayama. "Atrophic gastritis, Epstein-Barr virus infection, and Epstein-Barr virus-associated gastric carcinoma". Gastric Cancer 2, n.º 2 (31 de agosto de 1999): 101–8. http://dx.doi.org/10.1007/s101200050031.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

39

Xue, Ning, Shan Xing, Weiguo Ma, Jiahe Sheng, Zhiliang Huang y Qingxia Xu. "Combination of Plasma MIF and VCA-IgA Improves the Diagnostic Specificity for Patients With Nasopharyngeal Carcinoma". Technology in Cancer Research & Treatment 19 (1 de enero de 2020): 153303382093577. http://dx.doi.org/10.1177/1533033820935773.

Texto completo

Resumen

Introduction: The purpose of this study is to evaluate the diagnostic value of macrophage migration inhibitory factor in patients with nasopharyngeal carcinoma. Materials and Methods: The expression levels of macrophage migration inhibitory factor in nasopharyngeal carcinoma cell lines, tumor tissues, and plasma were measured by real-time polymerase chain reaction, Western blotting, enzyme-linked immunosorbent assay, and immunohistochemistry. Plasma Epstein-Barr virus viral capsid antigen was determined by immunoenzymatic techniques. Results: Both the messenger RNA and protein expression levels of macrophage migration inhibitory factor were upregulated in nasopharyngeal carcinoma cell lines and nasopharyngeal carcinoma tissues. Macrophage migration inhibitory factor in plasma was significantly elevated in patients with nasopharyngeal carcinoma compared to Epstein-Barr virus viral capsid antigen–negative and Epstein-Barr virus viral capsid antigen–positive healthy donors. The combination of macrophage migration inhibitory factor and Epstein-Barr virus viral capsid antigen was better for diagnosing nasopharyngeal carcinoma (area under receiver operating characteristic curve = 0.925, 95% CI: 0.898-0.951) than macrophage migration inhibitory factor (area under receiver operating characteristic curve = 0.778, 95% CI: 0.732-0.824) and Epstein-Barr virus viral capsid antigen. Combining macrophage migration inhibitory factor and Epstein-Barr virus viral capsid antigen had higher specificity (82.40% vs 69.96%) and higher positive predictive value (79.17% vs 67.44%) without an obvious reduction in sensitivity (95.25%) compared to Epstein-Barr virus viral capsid antigen alone. Macrophage migration inhibitory factor was highly expressed in nasopharyngeal carcinoma cell lines, whereas it was not associated with Epstein-Barr virus infection. The level of macrophage migration inhibitory factor in plasma was not related to the titer of Epstein-Barr virus viral capsid antigen. Conclusion: The combination of macrophage migration inhibitory factor and Epstein-Barr virus viral capsid antigen increases the specificity and positive predictive value of detecting nasopharyngeal carcinoma and improves the diagnostic accuracy of nasopharyngeal carcinoma in high-risk individuals.

Los estilos APA, Harvard, Vancouver, ISO, etc.

40

Holowaty, M. N. y L. Frappier. "HAUSP/USP7 as an Epstein–Barr virus target". Biochemical Society Transactions 32, n.º 5 (26 de octubre de 2004): 731–32. http://dx.doi.org/10.1042/bst0320731.

Texto completo

Resumen

USP7 (also called HAUSP) is a de-ubiquitinating enzyme recently identified as a key regulator of the p53–mdm2 pathway, which stabilizes both p53 and mdm2. We have discovered that the Epstein–Barr nuclear antigen 1 protein of Epstein–Barr virus binds with high affinity to USP7 and disrupts the USP7–p53 interaction. The results have important implications for the role of Epstein–Barr nuclear antigen 1 in the cellular immortalization that is typical of an Epstein–Barr virus latent infection.

Los estilos APA, Harvard, Vancouver, ISO, etc.

41

Montone, Kathleen T., Richard L. Hodinka y John E. Tomaszewski. "Identification of Epstein-Barr Virus Lytic and Latent RNA Transcripts in Post-transplant Lymphoproliferative Disorder". International Journal of Surgical Pathology 3, n.º 2 (octubre de 1995): 119–30. http://dx.doi.org/10.1177/106689699510030206.

Texto completo

Resumen

Thirty-three specimens from 25 transplant recipients with Epstein-Barr virus-associated lymphoproliferative disease were studied by in situ hybridization for 2 lytic and 4 latent Epstein-Barr virus transcripts. All specimens were found to contain at least 1 latent transcript while 28 were positive for at least 1 lytic transcript. The amount of Epstein-Barr virus infection and lytic activity varied with histopathology and number of involved sites. Patients with localized polymorphous disease contained the lowest number of infected cells with an almost equal lytic:latent ratio. Disseminated polymorphous and single and multisite monomorphous specimens showed a large latent cell population. Minimal lytic activity was seen in single site monomorphous specimens, but disseminated monomorphous specimens showed the highest levels of lytic transcripts. Most post-transplant lymphoproliferative disorder specimens demonstrate lytic Epstein-Barr virus transcripts, although the majority of cells contain latent Epstein-Barr virus. Lytic activity is highest in patients with disseminated disease. Lytic Epstein-Barr virus infection may aid in the development and maintenance of lymphoproliferative disorders in transplant recipients.

Los estilos APA, Harvard, Vancouver, ISO, etc.

42

Millichap, J. Gordon. "Epstein-Barr Virus Neurologic Complications". Pediatric Neurology Briefs 29, n.º 11 (17 de diciembre de 2015): 88. http://dx.doi.org/10.15844/pedneurbriefs-29-11-7.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

43

Richtsmeier, William J., Edward Gerard Wittels, Eric M. Mazur y Philip M. Sprinkle. "Epstein-Barr Virus-Associated Malignancies". CRC Critical Reviews in Clinical Laboratory Sciences 25, n.º 2 (enero de 1987): 105–36. http://dx.doi.org/10.3109/10408368709105879.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

44

Koch, Arjun D., Harry C. M. van den Bosch y Bert Bravenboer. "Epstein–Barr Virus–Associated Cholecystitis". Annals of Internal Medicine 146, n.º 11 (5 de junio de 2007): 826. http://dx.doi.org/10.7326/0003-4819-146-11-200706050-00024.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

45

Sangueza-Acosta, Martin y Erica Sandoval-Romero. "Epstein-Barr virus and skin". Anais Brasileiros de Dermatologia 93, n.º 6 (diciembre de 2018): 786–99. http://dx.doi.org/10.1590/abd1806-4841.20187021.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

46

Freixo, Cristiana, Sylvie Hermouet y Ana Margarida Neves. "Epstein-Barr Virus and Astrocytoma". Critical Reviews™ in Oncogenesis 24, n.º 4 (2019): 339–47. http://dx.doi.org/10.1615/critrevoncog.2020032954.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

47

Gandhi, Maher K. "Epstein–Barr virus-associated lymphomas". Expert Review of Anti-infective Therapy 4, n.º 1 (febrero de 2006): 77–89. http://dx.doi.org/10.1586/14787210.4.1.77.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

48

Herold, Jessica y Felipe Grimaldo. "Epstein-Barr Virus-induced Jaundice". Clinical Practice and Cases in Emergency Medicine 4, n.º 1 (21 de enero de 2020): 69–71. http://dx.doi.org/10.5811/cpcem.2019.10.45049.

Texto completo

Resumen

Infectious mononucleosis is primarily caused by Epstein-Barr virus (EBV) and is a common diagnosis made in emergency departments worldwide. Subclinical and transient transaminase elevations are a well-established sequela of EBV. However, acute cholestatic hepatitis is a rare complication. EBV infection should be considered as part of the differential diagnosis in patients with an obstructive pattern on liver function tests without evidence of biliary obstruction demonstrated on advanced imaging.

Los estilos APA, Harvard, Vancouver, ISO, etc.

49

Rickinson, A. B. "Epstein-Barr virus and lymphomagenesis". European Journal of Cancer 35 (septiembre de 1999): S388. http://dx.doi.org/10.1016/s0959-8049(99)81991-1.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

50

Macsween, Karen F. y Dorothy H. Crawford. "Epstein-Barr virus—recent advances". Lancet Infectious Diseases 3, n.º 3 (marzo de 2003): 131–40. http://dx.doi.org/10.1016/s1473-3099(03)00543-7.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Ofrecemos descuentos en todos los planes premium para autores cuyas obras están incluidas en selecciones literarias temáticas. ¡Contáctenos para obtener un código promocional único!